Swedbank AB Invests $3.42 Million in BioNTech SE Sponsored ADR $BNTX

Key Points

• Swedbank AB purchased 37,500 shares of BioNTech SE Sponsored ADR, valued at approximately $3.4 million, according to its recent 13F filing with the SEC.
• BioNTech's recent quarterly earnings report revealed a loss of ($1.60) per share, missing analysts' expectations, despite revenue of $306.46 million, which was significantly higher than anticipated.
• Several large investors have increased their stakes in BioNTech, with Bank of New York Mellon Corp's holdings jumping by 18,892.9% during the first quarter.

Swedbank AB purchased a new position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 37,500 shares of the company's stock, valued at approximately $3,415,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in BNTX. Bank of New York Mellon Corp grew its holdings in shares of BioNTech by 18,892.9% during the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after purchasing an additional 694,691 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of BioNTech by 94.6% during the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company's stock worth $108,859,000 after purchasing an additional 581,173 shares during the last quarter. Invesco Ltd. grew its holdings in shares of BioNTech by 643.7% during the first quarter. Invesco Ltd. now owns 645,142 shares of the company's stock worth $58,747,000 after purchasing an additional 558,389 shares during the last quarter. Millennium Management LLC grew its holdings in shares of BioNTech by 252.5% during the first quarter. Millennium Management LLC now owns 544,970 shares of the company's stock worth $49,625,000 after purchasing an additional 390,360 shares during the last quarter. Finally, Groupama Asset Managment grew its holdings in shares of BioNTech by 126.6% during the first quarter. Groupama Asset Managment now owns 196,544 shares of the company's stock worth $18,662,000 after purchasing an additional 109,819 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Trading Down 1.9%

BNTX traded down $1.84 during trading on Thursday, hitting $96.31. The company's stock had a trading volume of 1,595,902 shares, compared to its average volume of 969,117. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $129.27. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The stock's fifty day moving average price is $108.03 and its 200-day moving average price is $103.70. The firm has a market capitalization of $23.15 billion, a P/E ratio of -60.19 and a beta of 1.39.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. During the same period last year, the firm posted ($3.36) earnings per share. BioNTech's quarterly revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. Analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. JPMorgan Chase & Co. reduced their price target on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Morgan Stanley lifted their price objective on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Bank of America lifted their price objective on BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Finally, Leerink Partners set a $112.00 price objective on BioNTech in a research note on Monday, June 2nd. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, BioNTech presently has an average rating of "Moderate Buy" and a consensus price target of $135.22.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.